Tranilast

ApprovedSmall molecule

NNuon Therapeutics, Inc.

Tranilast is one of 171 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

170

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

HyperuricemiaActive, not recruiting

Esophageal StrictureActive, not recruiting

RosaceaActive, not recruiting

SarcoidosisActive, not recruiting

Cryopyrin-Associated Periodic SyndromeActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

HyperuricemiaPhase 2

Active, not recruiting

Esophageal StricturePhase 2

Active, not recruiting

RosaceaApproved

Active, not recruiting

SarcoidosisPhase 1

Active, not recruiting

Cryopyrin-Associated Periodic SyndromePhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Tranilast

NNuon Therapeutics, Inc.

Approved

2 2

Actemra

Simponi

19 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Ilaris

Novartis

Preclinical

3 8

Actos

Takeda

Preclinical

2 9

Celexa

AbbVie

Preclinical

1 10

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Esophageal Stricture

NCT06643689

Clinical

Trials by Indication[1]

Treatment2 trials

A Clinical Study of Tranilast in the Treatment of Scleredema Diabeticorum

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT03512873·56 enrolled

A Clinical Study of Tranilast in the Treatment of Mucinoses

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT03490708·56 enrolled

Hyperuricemia2 trials

Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia

Completed·NNuon Therapeutics, Inc.·Phase 2·NCT01052987·24 enrolled

Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia

Completed·NNuon Therapeutics, Inc.·Phase 2·NCT00995618·24 enrolled

Rheumatoid Arthritis2 trials

Effects of Tranilast on Pharmacokinetics of Methotrexate (MTX) in Patients With Rheumatoid Arthritis (RA)

Withdrawn·IImperial College London·Phase 1·NCT00717808

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

Completed·NNuon Therapeutics, Inc.·Phase 2·NCT00882024·250 enrolled

Nasopharyngeal Carcinoma1 trial

Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

Unknown status·JJian Guan·Phase 2·NCT05626829·18 enrolled

Rosacea1 trial

Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea

Enrolling by invitation·SSecond Affiliated Hospital of Xi'an Jiaotong University·Phase 4·NCT06307288·45 enrolled

4 more indications

Sarcoidosis1 trial

A Clinical Study of Tranilast in the Treatment of Sarcoidosis

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT03528070·56 enrolled

Cryopyrin-Associated Periodic Syndrome1 trial

A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT03923140·71 enrolled

Esophageal stricture1 trial

Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06643689·394 enrolled

LAM1 trial

Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI

Completed·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 4·NCT05130892·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Tranilast. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tranilast compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tranilast. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nuon Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNuon Therapeutics, Inc.

Tranilast

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Treatment2 trials

Hyperuricemia2 trials

Rheumatoid Arthritis2 trials

Nasopharyngeal Carcinoma1 trial

Rosacea1 trial

Sarcoidosis1 trial

Cryopyrin-Associated Periodic Syndrome1 trial

Esophageal stricture1 trial

LAM1 trial

References

Drug Info

Quick Facts

Related News